Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.

[1]  A. Bezjak,et al.  Predicting Radiation Esophagitis Using 18F‐FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Y. Ohe,et al.  Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. , 2016, International journal of radiation oncology, biology, physics.

[3]  W. Weber,et al.  Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. , 2015, Clinical lung cancer.

[4]  J. Bradley,et al.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. , 2015, International journal of radiation oncology, biology, physics.

[5]  D. Sher,et al.  Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non–Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  S. Hyun,et al.  Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. , 2015, AJR. American journal of roentgenology.

[7]  V. Grégoire,et al.  PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Jan-Jakob Sonke,et al.  Intra thoracic anatomical changes in lung cancer patients during the course of radiotherapy. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  C. Brink,et al.  Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer , 2014, Acta oncologica.

[10]  J. Aerts,et al.  Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  P. Baas,et al.  Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. , 2013, Clinical lung cancer.

[12]  J. Sonke,et al.  Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Shalini K Vinod,et al.  The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  R. Rami-Porta,et al.  Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the Staging Project Database of the International Association for the Study of Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Jan-Jakob Sonke,et al.  Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. , 2012, International journal of radiation oncology, biology, physics.

[16]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Maria Werner-Wasik,et al.  Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. , 2011, Clinical lung cancer.

[18]  N. O'Rourke,et al.  Concurrent chemoradiotherapy in non-small cell lung cancer. , 2010, The Cochrane database of systematic reviews.

[19]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Oyen,et al.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Joos V Lebesque,et al.  Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. , 2005, European journal of cancer.

[22]  Joos V Lebesque,et al.  Inclusion of geometric uncertainties in treatment plan evaluation. , 2002, International journal of radiation oncology, biology, physics.